Vimarsana
Biggest News Aggregation in the World

Page 14 - Immunic News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Immunic. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Immunic Today - Breaking & Trending Today

EQS-News: Immunic, Inc.: Immunic to Participate in Scientific and Investor Conferences in February - Vimarsana News

EQS-News: Immunic, Inc.: Immunic to Participate in Scientific and Investor Conferences in February

Issuer: Immunic, Inc. / Key word(s): Conference Immunic to Participate in Scientific and Investor Conferences in February 25.01.2023 / 12:30 CET/CEST The issuer is solely responsible

EQS-News: Immunic to Participate in Scientific and Investor Conferences in February - Vimarsana News

EQS-News: Immunic to Participate in Scientific and Investor Conferences in February

Issuer: Immunic, Inc. / Key word(s): Conference Immunic to Participate in Scientific and Investor Conferences in February 25.01.2023 / 12:30 CET/CEST The issuer is solely responsible for the content of this announcement. Immunic to Participate in Scientific and Investor Conferences in February N...

MUNIC EKKO Platform and Edge Computing OBD Dongles Power Smart Connect Project From ADAC (Allgemeiner Deutscher Automobil-Club) - Vimarsana News

MUNIC EKKO Platform and Edge Computing OBD Dongles Power Smart Connect Project From ADAC (Allgemeiner Deutscher Automobil-Club)

/PRNewswire/ -- Allgemeiner Deutscher Automobil-Club (ADAC), Europe's largest motoring association and Germany's largest auto club with 21 million members,...

EQS-News: Immunic, Inc.: Immunic Reports New Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis Supporting the Drug's Neuroprotective Potential - Vimarsana News

EQS-News: Immunic, Inc.: Immunic Reports New Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis Supporting the Drug's Neuroprotective Potential

Issuer: Immunic, Inc. / Key word(s): Study results/Conference Immunic Reports New Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis Supporting

Immunic Reports New Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis Supporting the Drug's Neuroprotective Potential - Vimarsana News

Immunic Reports New Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis Supporting the Drug's Neuroprotective Potential

/PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies focused...